FDA Approved: CAPLYTA — Supplemental Application (Intra-Cellular Therapies, Inc)

View source ↗

Summary

The FDA approved a supplemental application for CAPLYTA (lumateperone) from Intra-Cellular Therapies, Inc. The approval expands the drug’s labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• Caplyta (lumateperone)

Snippet

SUPPL AP for CAPLYTA (LUMATEPERONE)